Develops biologic therapeutic candidates for cancer patients using protein-engineering platforms.
10-K for FY2025, filed Mar 19, 2026We are a clinical-stage biopharmaceutical company with a pipeline of novel biologic therapeutic candidates, developed using our proprietary…View ↗
Ozekibart is a precisely engineered tetravalent therapeutic candidate targeting death-receptor 5, or DR5, a TNFRSF member, also known as…View ↗
We are currently investigating ozekibart in chondrosarcoma, Ewing sarcoma, and colorectal cancer. These are some of the most aggressive…View ↗
Partners pay for licenses and collaborative research, with additional payments tied to development, regulatory or commercial milestones and royalties on product sales; government agencies and private nonprofits have also provided grants. License and milestone payments are tied to the license transfer or milestone, research payments to work performed, and royalties to product sales.
10-K for FY2025, filed Mar 19, 2026The Company has historically generated revenue from its license and collaboration agreements with partners, as well as from grants from…View ↗
The Company enters into collaborative agreements with partners which may include the transfer of licenses, options to license, and the…View ↗
Typically, license fees, non-refundable upfront fees, and funding of research activities are considered fixed, while milestone payments…View ↗
The Company applies significant judgment when making estimates and assumptions under these agreements, including evaluating whether…View ↗
$1.3M
10-K for FY2025, filed Mar 19, 2026
$1.3M ↗
Partners enter license and collaboration agreements with the company; government agencies and private nonprofit organizations provide grants.
10-K for FY2025, filed Mar 19, 2026
No. It lost $140.1M in FY2025.
Competes with Crescendo Biologics, Molecular Partners, Precirix, Affibody Medical, Numab Therapeutics, GT Biopharma, Sanofi, Regeneron Pharmaceuticals, Adimab, Genmab, Macrogenics, Merus, Amgen, Xencor, Zymeworks, AstraZeneca, F. Hoffmann-La Roche, Pfizer, Merck &, and Novartis
10-K for FY2025, filed Mar 19, 2026Companies developing novel therapeutics based on sdAb or alternative scaffold product candidates, including Crescendo Biologics Ltd.…View ↗
Loading...